Medication-Taking Behaviors and Perceptions Among Adults With Heart Failure (from the REasons for Geographic And Racial Differences in Stroke Study).

Title
Publication TypeJournal Article
Year of Publication2019
AuthorsMefford MT, Sephel A, Van Dyke MK, Chen L, Durant RW, Brown TM, Fifolt M, Maya J, Goyal P, Safford MM, Levitan EB
JournalAm J Cardiol
Volume123
Issue10
Pagination1667-1674
Date Published2019 05 15
ISSN1879-1913
KeywordsAdrenergic beta-Antagonists, Aged, Aged, 80 and over, Ethnic Groups, Female, Heart Failure, Humans, Incidence, Male, Medication Adherence, Middle Aged, Perception, Stroke, Stroke Volume, United States
Abstract

Medication regimens in adults with heart failure (HF) are complex which can complicate patient adherence. Individuals with HF frequently use beta blockers (BBs) for multiple indications, including hypertension and HF, but BBs can have significant side effects that may affect their use. We examined medication-taking behaviors and perceptions in individuals with HF with a particular focus on BBs. A mailed survey on medication use was administered to US adults with HF enrolled in the REasons for Geographic And Racial Differences in Stroke study. Among 518 respondents, 357 (69%) reported taking a BB. Nearly half (42%) reported taking ≥10 medications per day. However, 45% indicated that they did not miss any days taking medications, and over 85% reported willingness to take additional medications to prevent further healthcare encounters. Participants' perceptions of BB symptoms varied, but 56% of those who reported experiencing symptoms did not discuss this with their healthcare providers. Adults who experienced HF hospitalization had higher odds of reporting taking BBs to treat HF (odds ratio 1.51, 95% confidence interval 1.19, 1.91). Adults with hypertension were also likely to report taking BBs to treat high blood pressure (odds ratio 2.42, 95% confidence interval 1.79, 3.26). In conclusion, despite extensive medication regimens, individuals with HF were willing to take additional medications for their disease. Participant recognition of BB use for treating HF and co-morbidities was high, yet many do not report side effects to healthcare providers. In conclusion, better understanding of patients' medication-taking behaviors and perceptions may facilitate optimization of HF treatments.

DOI10.1016/j.amjcard.2019.02.024
Alternate JournalAm. J. Cardiol.
PubMed ID30879609
PubMed Central IDPMC6488419
Grant ListR03 AG056446 / AG / NIA NIH HHS / United States
L30 AG060521 / AG / NIA NIH HHS / United States
T32 HS013852 / HS / AHRQ HHS / United States
U01 NS041588 / NS / NINDS NIH HHS / United States
R01 HL080477 / HL / NHLBI NIH HHS / United States